UPDATE: Aeterna Zentaris Affirms Business, Prospects Remain Fundamentally Strong

Loading...
Loading...
Aeterna Zentaris Inc.
AEZ
(the "Company"), affirms that its business and prospects remain fundamentally strong and highlights the following developments: Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to continue the ZoptEC Phase 3 clinical program to completion following review of the final interim efficacy and safety data Zoptrex™ met Phase 2 Primary Endpoint in men with heavily pretreated castration- and Taxane-resistant prostate cancer First patient enrolled in the confirmatory Phase 3 clinical trial of Macrilen™ Promotion of Saizen® and EstroGel® by the Company's sales force continues to show promise Dilution from Series B Share Purchase Warrants has been substantially eliminated Commenting about the fundamentals of the Company's business, Chairman, President and Chief Executive Officer David A Dodd stated, "Yesterday's announcement regarding corporate developments, which was required by IIROC on behalf of the Toronto Stock Exchange, caused some to question the fundamentals of our business. I want to reiterate that we believe the fundamentals remain strong. We have two products in Phase 3. One of the products, Zoptrex™, is in the late stage of Phase 3. We instituted a confirmatory Phase 3 clinical trial of Macrilen™ after a panel of US and EU endocrinology experts advised us to continue
See full press release
Posted In: NewsPress Releases
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...